Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius AGSARTF 84 3-1 Month Momentum % is -3.84% as of Jul. 14, 2026. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $273.77 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 845 Medical Devices & Instruments companies, Sartorius AG ranks better than 79.29% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-14), Sartorius AG's 3-1 Month Momentum % is -3.84%.
The industry rank for Sartorius AG's 3-1 Month Momentum % or its related term are showing as below:
SARTF's 3-1 Month Momentum % is ranked better than 79.29% of 845
companies
in the Medical Devices & Instruments industry
Industry Median: -7.24
vs SARTF: -3.84
Sartorius AG (OTCPK:SARTF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Sartorius AG 3-1 Month Momentum % Related Terms
SARTF vs ISRG, BDX, MDLN: 3-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Sartorius AG's 3-1 Month Momentum % falls into.
Sartorius AG (OTCPK:SARTF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a 3-1 Month Momentum % of -3.84% as of Jul. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sartorius AG and its competitors. According to the industry distribution chart, Sartorius AG ranks #175 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 20.7%.
Is Sartorius AG's 3-1 Month Momentum % too high?
Sartorius AG's current 3-1 Month Momentum % is -3.84%. Based on the distribution chart, Sartorius AG ranks #175 out of 845 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's 3-1 Month Momentum % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #175 out of 845 companies for 3-1 Month Momentum %. This places Sartorius AG in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sartorius AG and its competitors. Sartorius AG's current 3-1 Month Momentum % is -3.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $273.77, compared to a current price of $212.80 — trading 22.3% below its estimated fair value. The current 3-1 Month Momentum % is -3.84%. Sartorius AG's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Sartorius AG (SARTF), the current 3-1 Month Momentum % is -3.84% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 22.3% below its estimated GF Value™ of $273.77.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
3-1 Month Momentum %: -3.84%
GF Value™: $273.77 vs. price of $212.80 (22.3% below fair value)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score
Get the complete analysis for SARTF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
